[
  {
    "ts": "2025-11-18T08:30:00+00:00",
    "headline": "[Latest] Global NUT Midline Carcinoma Treatment Market Size/Share Worth USD 93.34 Billion by 2034 at a 15.26% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global NUT Midline Carcinoma Treatment Market size & share revenue was valued at approximately USD 22.67 Billion in 2024 and is expected to reach USD 26.13 Billion in 2025 and is expected to reach around USD 93.34 Billion by 2034, at a CAGR of 15.26% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Merck & Co.",
    "url": "https://finance.yahoo.com/news/latest-global-nut-midline-carcinoma-083000107.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "a44e377f-4362-3d10-a37c-7c7e8b8b2108",
      "content": {
        "id": "a44e377f-4362-3d10-a37c-7c7e8b8b2108",
        "contentType": "STORY",
        "title": "[Latest] Global NUT Midline Carcinoma Treatment Market Size/Share Worth USD 93.34 Billion by 2034 at a 15.26% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT)",
        "description": "",
        "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global NUT Midline Carcinoma Treatment Market size & share revenue was valued at approximately USD 22.67 Billion in 2024 and is expected to reach USD 26.13 Billion in 2025 and is expected to reach around USD 93.34 Billion by 2034, at a CAGR of 15.26% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Merck & Co.",
        "pubDate": "2025-11-18T08:30:00Z",
        "displayTime": "2025-11-18T08:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891",
          "originalWidth": 2514,
          "originalHeight": 1281,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2CrZC42kgw2SjdY2CY6ucw--~B/aD0xMjgxO3c9MjUxNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891.cf.webp",
              "width": 2514,
              "height": 1281,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/91DUI4_rVm8Et9pJYV6I4Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/latest-global-nut-midline-carcinoma-083000107.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/latest-global-nut-midline-carcinoma-083000107.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "CCCC"
            },
            {
              "symbol": "GSK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T11:24:15+00:00",
    "headline": "Nuvalent aiming for approval on pivotal trial data for NSCLC candidate",
    "summary": "Nuvalent will discuss the data for TKI pre-treated ALK-positive NSCLC patients with the FDA in a pre-NDA meeting",
    "url": "https://www.clinicaltrialsarena.com/news/nuvalent-aiming-for-approval-on-pivotal-trial-data-for-nsclc-candidate/",
    "source": "Clinical Trials Arena",
    "provider": "yfinance",
    "raw": {
      "id": "80211404-cd60-3ab8-a4ea-f40c7343a47a",
      "content": {
        "id": "80211404-cd60-3ab8-a4ea-f40c7343a47a",
        "contentType": "STORY",
        "title": "Nuvalent aiming for approval on pivotal trial data for NSCLC candidate",
        "description": "",
        "summary": "Nuvalent will discuss the data for TKI pre-treated ALK-positive NSCLC patients with the FDA in a pre-NDA meeting",
        "pubDate": "2025-11-18T11:24:15Z",
        "displayTime": "2025-11-18T11:24:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/clinical_trials_arena_396/63ca4de005aa172b9981fcfc34b2feab",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "Nuvalent is also investigating the drug in a Phase III trial in TKI-naive ALK-positive NSCLC patients. Image credit: Piotr Swat / Shutterstock.com.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_fC8.gB8PS3DT4_GS1PpRg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/63ca4de005aa172b9981fcfc34b2feab.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3epJEnILlJO4GpKn7CfsCA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/clinical_trials_arena_396/63ca4de005aa172b9981fcfc34b2feab.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Clinical Trials Arena",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.clinicaltrialsarena.com/news/nuvalent-aiming-for-approval-on-pivotal-trial-data-for-nsclc-candidate/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nuvalent-aiming-approval-pivotal-trial-112415367.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NUVL"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T10:30:00+00:00",
    "headline": "The Weight-Loss Craze Is About to Mint a Trillion-Dollar Company",
    "summary": "Eli Lilly  might soon join them for a far different reason: the weight-loss bonanza.  This year, Lilly has moved sharply ahead, securing Medicare access while widening its lead over Wegovy maker  Novo Nordisk  That is why investors shouldn’t assume the rally stops at a trillion.  Lilly only began selling its weight-loss drug Zepbound in late 2023, and the Food and Drug Administration only declared an end to a supply shortage of obesity drugs last year.",
    "url": "https://www.wsj.com/health/pharma/the-weight-loss-craze-is-about-to-mint-a-trillion-dollar-company-f92d51d0?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "ac2e96e5-a067-3c02-a2cf-3819f053faab",
      "content": {
        "id": "ac2e96e5-a067-3c02-a2cf-3819f053faab",
        "contentType": "STORY",
        "title": "The Weight-Loss Craze Is About to Mint a Trillion-Dollar Company",
        "description": "",
        "summary": "Eli Lilly  might soon join them for a far different reason: the weight-loss bonanza.  This year, Lilly has moved sharply ahead, securing Medicare access while widening its lead over Wegovy maker  Novo Nordisk  That is why investors shouldn’t assume the rally stops at a trillion.  Lilly only began selling its weight-loss drug Zepbound in late 2023, and the Food and Drug Administration only declared an end to a supply shortage of obesity drugs last year.",
        "pubDate": "2025-11-18T10:30:00Z",
        "displayTime": "2025-11-18T10:30:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ac2e96e5-a067-3c02-a2cf-3819f053faab/the-weight-loss-craze-is.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/4e935d45541721d11f61e7c5084f900e",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BONe.IvmYz1PI80IiJvYow--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/4e935d45541721d11f61e7c5084f900e.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lZg8ZTfmPAKqUBBdR2wmmg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/4e935d45541721d11f61e7c5084f900e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/the-weight-loss-craze-is-about-to-mint-a-trillion-dollar-company-f92d51d0?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T03:31:11+00:00",
    "headline": "Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Pfizer (NYSE:PFE)",
    "summary": "As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers.",
    "url": "https://finance.yahoo.com/news/branded-pharmaceuticals-stocks-q3-recap-033111580.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "3541cdd2-1828-3a62-bc5e-9970dbc82626",
      "content": {
        "id": "3541cdd2-1828-3a62-bc5e-9970dbc82626",
        "contentType": "STORY",
        "title": "Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Pfizer (NYSE:PFE)",
        "description": "",
        "summary": "As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers.",
        "pubDate": "2025-11-18T03:31:11Z",
        "displayTime": "2025-11-18T03:31:11Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "PFE Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o3tZoPUio75qXATbHoc_Hg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o5rZqD7vIoFGnsFYAS_Ztw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/branded-pharmaceuticals-stocks-q3-recap-033111580.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/branded-pharmaceuticals-stocks-q3-recap-033111580.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T15:20:00+00:00",
    "headline": "Microscopic Polyangiitis Market Research Report 2025-2035, Competitive Analysis of Roche, Amgen, Teva, Novartis, Baxter, Amerigen Pharma, InflaRx, Biogen, Pfizer, Celltrion",
    "summary": "The Global Microscopic Polyangiitis (MPA) market is experiencing growth driven by the adoption of biologic therapies, which offer targeted mechanisms and improved relapse prevention. MPA, a rare ANCA-associated vasculitis, affects small blood vessels, posing risks to vital organs such as kidneys and lungs. Diagnosis requires ANCA testing and biopsies, with treatment involving corticosteroids, cyclophosphamide, and rituximab, alongside new therapies like avacopan. Despite challenges like high bio",
    "url": "https://finance.yahoo.com/news/microscopic-polyangiitis-market-research-report-152000128.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "5a956957-cf27-33cb-bbcd-a1600c03f789",
      "content": {
        "id": "5a956957-cf27-33cb-bbcd-a1600c03f789",
        "contentType": "STORY",
        "title": "Microscopic Polyangiitis Market Research Report 2025-2035, Competitive Analysis of Roche, Amgen, Teva, Novartis, Baxter, Amerigen Pharma, InflaRx, Biogen, Pfizer, Celltrion",
        "description": "",
        "summary": "The Global Microscopic Polyangiitis (MPA) market is experiencing growth driven by the adoption of biologic therapies, which offer targeted mechanisms and improved relapse prevention. MPA, a rare ANCA-associated vasculitis, affects small blood vessels, posing risks to vital organs such as kidneys and lungs. Diagnosis requires ANCA testing and biopsies, with treatment involving corticosteroids, cyclophosphamide, and rituximab, alongside new therapies like avacopan. Despite challenges like high bio",
        "pubDate": "2025-11-18T15:20:00Z",
        "displayTime": "2025-11-18T15:20:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/microscopic-polyangiitis-market-research-report-152000128.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/microscopic-polyangiitis-market-research-report-152000128.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ROG.SW"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "TEVA.TA"
            },
            {
              "symbol": "NOVN.SW"
            },
            {
              "symbol": "BAX"
            },
            {
              "symbol": "IFRX"
            },
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T15:12:00+00:00",
    "headline": "Hemophilia A Research Report 2025-2035: Market Driven by Innovation from Alnylam, Pfizer, Roche, Novo Nordisk, and Takeda as Next-Generation Therapies and Emerging Market Expansion Bolsters Growth",
    "summary": "Hemophilia A, a rare genetic disorder marked by a deficiency of clotting factor VIII, leads to prolonged bleeding and joint damage. Enhanced treatment options, like extended half-life clotting factors and gene therapy, are revolutionizing patient outcomes through less frequent dosing and potential long-term solutions. Rising awareness and improved diagnostics hasten early detection, boosting demand. However, high treatment costs and regulatory hurdles present challenges. Key players like Alnylam",
    "url": "https://finance.yahoo.com/news/hemophilia-research-report-2025-2035-151200716.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "3c4d9181-d3af-313a-bffb-e86e61d932d5",
      "content": {
        "id": "3c4d9181-d3af-313a-bffb-e86e61d932d5",
        "contentType": "STORY",
        "title": "Hemophilia A Research Report 2025-2035: Market Driven by Innovation from Alnylam, Pfizer, Roche, Novo Nordisk, and Takeda as Next-Generation Therapies and Emerging Market Expansion Bolsters Growth",
        "description": "",
        "summary": "Hemophilia A, a rare genetic disorder marked by a deficiency of clotting factor VIII, leads to prolonged bleeding and joint damage. Enhanced treatment options, like extended half-life clotting factors and gene therapy, are revolutionizing patient outcomes through less frequent dosing and potential long-term solutions. Rising awareness and improved diagnostics hasten early detection, boosting demand. However, high treatment costs and regulatory hurdles present challenges. Key players like Alnylam",
        "pubDate": "2025-11-18T15:12:00Z",
        "displayTime": "2025-11-18T15:12:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/hemophilia-research-report-2025-2035-151200716.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/hemophilia-research-report-2025-2035-151200716.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ALNY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "ROG.SW"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "4502.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T15:10:00+00:00",
    "headline": "Hemophilia B Research Report 2025-2035: Market Led by UniQure, Pfizer, Novo Nordisk, HEMA Biologics, and Alnylam Pharmaceuticals as Next-Generation Therapies and R&D Investment Drive Innovation",
    "summary": "The Hemophilia B market is growing rapidly due to advancements in gene therapy and diagnostics. This rare genetic disorder, caused by F9 gene mutations, primarily affects males. Revolutionary treatments like Hemgenix and Beqvez offer potential functional cures by reducing bleeding rates. Early detection using next-generation sequencing enhances patient management and personalized care. Despite challenges such as high costs and limited long-term safety data, leading companies like UniQure and Pfi",
    "url": "https://finance.yahoo.com/news/hemophilia-b-research-report-2025-151000135.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "872165ea-82b1-33ba-b41b-a8a88bd3026f",
      "content": {
        "id": "872165ea-82b1-33ba-b41b-a8a88bd3026f",
        "contentType": "STORY",
        "title": "Hemophilia B Research Report 2025-2035: Market Led by UniQure, Pfizer, Novo Nordisk, HEMA Biologics, and Alnylam Pharmaceuticals as Next-Generation Therapies and R&D Investment Drive Innovation",
        "description": "",
        "summary": "The Hemophilia B market is growing rapidly due to advancements in gene therapy and diagnostics. This rare genetic disorder, caused by F9 gene mutations, primarily affects males. Revolutionary treatments like Hemgenix and Beqvez offer potential functional cures by reducing bleeding rates. Early detection using next-generation sequencing enhances patient management and personalized care. Despite challenges such as high costs and limited long-term safety data, leading companies like UniQure and Pfi",
        "pubDate": "2025-11-18T15:10:00Z",
        "displayTime": "2025-11-18T15:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/hemophilia-b-research-report-2025-151000135.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/hemophilia-b-research-report-2025-151000135.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "ALNY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T16:11:13+00:00",
    "headline": "Pfizer (PFE): Exploring Valuation After Recent Momentum in Share Price",
    "summary": "Pfizer (PFE) shares have shown resilience, with a modest uptick over the past week and month. Investors are keeping an eye on the stock’s performance as the company navigates market trends and changing sentiment. See our latest analysis for Pfizer. Despite a challenging year for many large-cap healthcare names, Pfizer's recent momentum hints at a shift in sentiment. While the share price is still down for the year to date, the one-year total shareholder return has turned positive. This...",
    "url": "https://finance.yahoo.com/news/pfizer-pfe-exploring-valuation-recent-161113541.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "b687ee6b-8090-3210-bdc4-5fb2caa527cb",
      "content": {
        "id": "b687ee6b-8090-3210-bdc4-5fb2caa527cb",
        "contentType": "STORY",
        "title": "Pfizer (PFE): Exploring Valuation After Recent Momentum in Share Price",
        "description": "",
        "summary": "Pfizer (PFE) shares have shown resilience, with a modest uptick over the past week and month. Investors are keeping an eye on the stock’s performance as the company navigates market trends and changing sentiment. See our latest analysis for Pfizer. Despite a challenging year for many large-cap healthcare names, Pfizer's recent momentum hints at a shift in sentiment. While the share price is still down for the year to date, the one-year total shareholder return has turned positive. This...",
        "pubDate": "2025-11-18T16:11:13Z",
        "displayTime": "2025-11-18T16:11:13Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pfe-exploring-valuation-recent-161113541.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pfe-exploring-valuation-recent-161113541.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T15:37:00+00:00",
    "headline": "Renal Anemia Market Research Report 2025-2035, Competitive Analysis of Amgen, Sandoz, Pfizer, GlaxoSmithKline, Akebia Therapeutics, and Astellas Pharma",
    "summary": "The global renal anemia market is experiencing significant growth, driven by advancements in therapeutic options, increased diagnostic accuracy, and enhanced healthcare investments in the U.S., Europe, and emerging markets. The market is reshaped by the expansion of erythropoiesis-stimulating agents (ESAs), iron supplements, and novel oral hypoxia-inducible factor prolyl-hydroxylase inhibitors (HIF-PHIs). Rising awareness about untreated renal anemia complications, such as fatigue, fuels the dem",
    "url": "https://finance.yahoo.com/news/renal-anemia-market-research-report-153700490.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "9629426b-0c7a-35b3-9ec7-3493d805a1a3",
      "content": {
        "id": "9629426b-0c7a-35b3-9ec7-3493d805a1a3",
        "contentType": "STORY",
        "title": "Renal Anemia Market Research Report 2025-2035, Competitive Analysis of Amgen, Sandoz, Pfizer, GlaxoSmithKline, Akebia Therapeutics, and Astellas Pharma",
        "description": "",
        "summary": "The global renal anemia market is experiencing significant growth, driven by advancements in therapeutic options, increased diagnostic accuracy, and enhanced healthcare investments in the U.S., Europe, and emerging markets. The market is reshaped by the expansion of erythropoiesis-stimulating agents (ESAs), iron supplements, and novel oral hypoxia-inducible factor prolyl-hydroxylase inhibitors (HIF-PHIs). Rising awareness about untreated renal anemia complications, such as fatigue, fuels the dem",
        "pubDate": "2025-11-18T15:37:00Z",
        "displayTime": "2025-11-18T15:37:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/renal-anemia-market-research-report-153700490.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/renal-anemia-market-research-report-153700490.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "SDZ.SW"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "GSK.L"
            },
            {
              "symbol": "AKBA"
            },
            {
              "symbol": "4503.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T15:30:00+00:00",
    "headline": "Hemophilia Research Analysis Report 2025-2035: Market Advances as Leading Players Accelerate Gene Therapy Innovation and Strategic Partnerships, Led by CSL Behring, Takeda, and Pfizer",
    "summary": "The global hemophilia market is experiencing robust growth, fueled by advances in gene therapy and recombinant clotting factors. Increased awareness and healthcare investment worldwide are expanding access to innovative treatments such as extended half-life therapies and novel biologics, enhancing patient outcomes. The U.S. market drives this expansion, supported by a strong healthcare infrastructure and evolving regulatory landscape. However, high therapy costs and regulatory hurdles remain cha",
    "url": "https://finance.yahoo.com/news/hemophilia-research-analysis-report-2025-153000281.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "992d6176-23e4-36df-8d07-89a19aafe883",
      "content": {
        "id": "992d6176-23e4-36df-8d07-89a19aafe883",
        "contentType": "STORY",
        "title": "Hemophilia Research Analysis Report 2025-2035: Market Advances as Leading Players Accelerate Gene Therapy Innovation and Strategic Partnerships, Led by CSL Behring, Takeda, and Pfizer",
        "description": "",
        "summary": "The global hemophilia market is experiencing robust growth, fueled by advances in gene therapy and recombinant clotting factors. Increased awareness and healthcare investment worldwide are expanding access to innovative treatments such as extended half-life therapies and novel biologics, enhancing patient outcomes. The U.S. market drives this expansion, supported by a strong healthcare infrastructure and evolving regulatory landscape. However, high therapy costs and regulatory hurdles remain cha",
        "pubDate": "2025-11-18T15:30:00Z",
        "displayTime": "2025-11-18T15:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/hemophilia-research-analysis-report-2025-153000281.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/hemophilia-research-analysis-report-2025-153000281.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "4502.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T15:28:00+00:00",
    "headline": "Pleural Effusion Market Research Report 2025-2035: Novatech, Sanofi, and Pfizer Lead Innovation Through Strategic Partnerships and R&D Expansion",
    "summary": "The global pleural effusion market is experiencing steady growth due to advancements in medical treatments and diagnostic tools, increased awareness of respiratory health, and a rising demand for effective management solutions. Key drivers include the development of advanced drainage systems, anti-inflammatory drugs, and minimally invasive treatments like thoracentesis and pleurodesis. As awareness of pleural effusion's risks increases, early detection and intervention remain crucial. Despite ch",
    "url": "https://finance.yahoo.com/news/pleural-effusion-market-research-report-152800462.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "31b9d91b-c040-349f-8c10-2c3b86753178",
      "content": {
        "id": "31b9d91b-c040-349f-8c10-2c3b86753178",
        "contentType": "STORY",
        "title": "Pleural Effusion Market Research Report 2025-2035: Novatech, Sanofi, and Pfizer Lead Innovation Through Strategic Partnerships and R&D Expansion",
        "description": "",
        "summary": "The global pleural effusion market is experiencing steady growth due to advancements in medical treatments and diagnostic tools, increased awareness of respiratory health, and a rising demand for effective management solutions. Key drivers include the development of advanced drainage systems, anti-inflammatory drugs, and minimally invasive treatments like thoracentesis and pleurodesis. As awareness of pleural effusion's risks increases, early detection and intervention remain crucial. Despite ch",
        "pubDate": "2025-11-18T15:28:00Z",
        "displayTime": "2025-11-18T15:28:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pleural-effusion-market-research-report-152800462.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pleural-effusion-market-research-report-152800462.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SAN.PA"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T16:03:00+00:00",
    "headline": "J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B",
    "summary": "J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.",
    "url": "https://finance.yahoo.com/news/j-j-joins-pharma-m-160300242.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "3c349984-2127-394c-af6e-5b9be1a63904",
      "content": {
        "id": "3c349984-2127-394c-af6e-5b9be1a63904",
        "contentType": "STORY",
        "title": "J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B",
        "description": "",
        "summary": "J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.",
        "pubDate": "2025-11-18T16:03:00Z",
        "displayTime": "2025-11-18T16:03:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/ca9d72216d7bb42fc496430c3df29b41",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hD1XqSSX7ulRknhxAtE3Fg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ca9d72216d7bb42fc496430c3df29b41.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WurdES47e08.qoEQbQD.wQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ca9d72216d7bb42fc496430c3df29b41.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/j-j-joins-pharma-m-160300242.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/j-j-joins-pharma-m-160300242.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T15:59:00+00:00",
    "headline": "Pfizer Trading Above 50-Day SMA: Is it a Good Time to Buy the Stock?",
    "summary": "PFE trades above its 50-day SMA on recent gains from the Metsera acquisition and a drug pricing agreement with the U.S. administration.",
    "url": "https://finance.yahoo.com/news/pfizer-trading-above-50-day-155900167.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "20d71a32-421d-3553-b3fe-030fcb42b2d3",
      "content": {
        "id": "20d71a32-421d-3553-b3fe-030fcb42b2d3",
        "contentType": "STORY",
        "title": "Pfizer Trading Above 50-Day SMA: Is it a Good Time to Buy the Stock?",
        "description": "",
        "summary": "PFE trades above its 50-day SMA on recent gains from the Metsera acquisition and a drug pricing agreement with the U.S. administration.",
        "pubDate": "2025-11-18T15:59:00Z",
        "displayTime": "2025-11-18T15:59:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YqcOBKMNrThKvJSga1KIbw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_Vj9Bix098SQE5mY9G0P2w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-trading-above-50-day-155900167.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-trading-above-50-day-155900167.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T20:44:55+00:00",
    "headline": "Sector Update: Health Care Stocks Rise Late Afternoon",
    "summary": "Health care stocks rose late Tuesday afternoon, with the NYSE Health Care Index up 0.3% and the Heal",
    "url": "https://finance.yahoo.com/news/sector-health-care-stocks-rise-204455650.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "9d64ed3a-d7d7-3083-b8bc-3bd04d2576cc",
      "content": {
        "id": "9d64ed3a-d7d7-3083-b8bc-3bd04d2576cc",
        "contentType": "STORY",
        "title": "Sector Update: Health Care Stocks Rise Late Afternoon",
        "description": "",
        "summary": "Health care stocks rose late Tuesday afternoon, with the NYSE Health Care Index up 0.3% and the Heal",
        "pubDate": "2025-11-18T20:44:55Z",
        "displayTime": "2025-11-18T20:44:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-rise-204455650.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-rise-204455650.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "XLV"
            },
            {
              "symbol": "MDT"
            },
            {
              "symbol": "ARWR"
            },
            {
              "symbol": "DX-Y.NYB"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T20:33:00+00:00",
    "headline": "Novo Nordisk, Eli Lilly Weight Loss Price War Heats Up. Why It’s a Worry for the Stocks.",
    "summary": "Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.",
    "url": "https://www.barrons.com/articles/novo-nordisk-eli-lilly-stocks-price-war-94e485fc?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "6aecc3f9-9b19-3d20-92d4-db4e66863a70",
      "content": {
        "id": "6aecc3f9-9b19-3d20-92d4-db4e66863a70",
        "contentType": "STORY",
        "title": "Novo Nordisk, Eli Lilly Weight Loss Price War Heats Up. Why It’s a Worry for the Stocks.",
        "description": "",
        "summary": "Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.",
        "pubDate": "2025-11-18T20:33:00Z",
        "displayTime": "2025-11-18T20:33:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/6aecc3f9-9b19-3d20-92d4-db4e66863a70/novo-nordisk-eli-lilly.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/bf563ae6d7267a07a7bfe31093ce819f",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0Lw2h2_aT5wIBP3VTSFOYg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/bf563ae6d7267a07a7bfe31093ce819f.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8jxA17YtWu8QRQ5L.62AfA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/bf563ae6d7267a07a7bfe31093ce819f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/novo-nordisk-eli-lilly-stocks-price-war-94e485fc?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T19:23:00+00:00",
    "headline": "Can AI Drive Peloton's Comeback?",
    "summary": "The market is hopping with interesting news.",
    "url": "https://www.fool.com/investing/2025/11/18/can-ai-drive-pelotons-comeback/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "0888ae95-c86e-3b61-9b94-1fab7cf99cca",
      "content": {
        "id": "0888ae95-c86e-3b61-9b94-1fab7cf99cca",
        "contentType": "STORY",
        "title": "Can AI Drive Peloton's Comeback?",
        "description": "",
        "summary": "The market is hopping with interesting news.",
        "pubDate": "2025-11-18T19:23:00Z",
        "displayTime": "2025-11-18T19:23:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/c98516745505a7fec56fa5dc1142929a",
          "originalWidth": 1920,
          "originalHeight": 1080,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LtyjMdgdx7ekukqnaHUMxg--~B/aD0xMDgwO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/motleyfool.com/c98516745505a7fec56fa5dc1142929a.cf.webp",
              "width": 1920,
              "height": 1080,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5nZlxfm712VDv73Z.nvzVw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/c98516745505a7fec56fa5dc1142929a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/18/can-ai-drive-pelotons-comeback/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ai-drive-pelotons-comeback-192300231.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PTON"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "COIN"
            },
            {
              "symbol": "NVDA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]